Browse our 650+ Publications​

Latest Publications

Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.

Wang M, et al.
Journal of Clinical Oncology
June 2022
Authors and Affiliates
Michael Wang, MD1; Javier Munoz, MD, MS, MBA2; Andre Goy, MD, MS3; Frederick L. Locke, MD4; Caron A. Jacobson, MD, MMSc5;Brian T. Hill, MD, PhD6; John M. Timmerman, MD7; Houston Holmes, MD, MBA8; Samantha Jaglowski, MD9; Ian W. Flinn, MD, PhD10;Peter A. McSweeney, MB, ChB11; David B. Miklos, MD, PhD12; John M. Pagel, MD, PhD, DSc13; Marie Jose Kersten, MD, PhD ´ 14;Krimo Bouabdallah, MD15; Rashmi Khanal, MD16; Max S. Topp, MD17; Roch Houot, MD, PhD18; Amer Beitinjaneh, MD19;Weimin Peng, PhD20; Xiang Fang, PhD20; Rhine R. Shen, PhD20; Rubina Siddiqi, PhD20; Ioana Kloos, MD20; and Patrick M. Reagan, MD21 1The University of Texas MD Anderson Cancer Center, Houston, TX 2Banner MD Anderson Cancer Center, Gilbert, AZ 3John Theurer Cancer Center, Hackensack University, Hackensack, NJ 4Moffitt Cancer Center, Tampa, FL 5Dana-Farber Cancer Institute, Boston, MA 6Cleveland Clinic Foundation, Cleveland, OH 7David Geffen School of Medicine at UCLA, Los Angeles, CA 8Texas Oncology, Dallas, TX 9The Ohio State University Comprehensive Cancer Center, Columbus, OH 10Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 11Colorado Blood Cancer Institute, Denver, CO 12Stanford University School of Medicine, Stanford, CA 13Swedish Cancer Institute, Seattle, WA 14Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, the Netherlands, on behalf of HOVON/LLPC 15CHU Bordeaux, Service d’Hematologie et th ´ erapie Cellulaire, ´Bordeaux, France 16Fox Chase Cancer Center, Philadelphia, PA 17Medizinische Klinik und Poliklinik II, Universitatsklinikum W ¨ urzburg, ¨Wurzburg, Germany ¨ 18CHU Rennes, Universite Rennes, INSERM & EFS, Rennes, France ´ 19University of Miami, Miami, FL 20Kite, a Gilead Company, Santa Monica, CA 21University of Rochester Medical Center, Rochester, NY

Combining CD34+ stem cell selection with prophylactic pathogen and leukemia directed T-cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant

Gottlieb DJ, et al.
American Journal of Hematology
May 2022
Authors and Affiliates
David J Gottlieb 1,2,3,4, Gaurav Sutrave 1,2,4, Wei Jiang 1,2, Selmir Avdic 2,4, Janine A Street 2,4, Renee Simms 1,2, Leighton E Clancy 1,4,5, Vicki Antonenas 5, Brian S Gloss 6, Caroline Bateman 2,4,7, David C Bishop 1,2,4, Kenneth P Micklethwaite 1,2,3,5, Emily Blyth 1,2,3,4; 1 Blood Transplant and Cell Therapies Program, Westmead Hospital, Sydney, New South Wales. 2 Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales. 3 Department of Haematology, Westmead Hospital, Sydney, New South Wales. 4 T-Cell Therapies Group, Westmead Institute for Medical Research, Sydney, New South Wales. 5 Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead, New South Wales, Australia. 6 Westmead Research Hub, Westmead Institute for Medical Research, Sydney, New South Wales, Australia. 7 Departments of Haematology and Oncology, Children's Hospital at Westmead, Sydney, New South Wales, Australia.

Comprehensive analysis of TCR repertoire of COVID-19 patients in different infected stage

Wang G, et al.
Genes & Genomics
May 2022
Authors and Affiliates
Guangyu Wang #,1, Yongsi Wang #,2, Shaofeng Jiang #,3, Wentao Fan 2, Chune Mo 1, Weiwei Gong 1, Hui Chen 2, Dan He 2, Jinqing Huang 3, Minglin Ou 4,5, Xianliang Hou 6; 1 Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. 2 Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou, China. 3 Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, 541199, Guangxi, China. 4 Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. minglinou@glmc.edu.cn. 5 Guangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, 541199, Guangxi, China. minglinou@glmc.edu.cn. 6 Central Laboratory, Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, 541199, China. houxianliang@zju.edu.cn. # Contributed equally.

Serial Analysis of the T-Cell Receptor β-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy

Towlerton AMH, et al.
Frontiers in Immunology
May 2022
Authors and Affiliates
Andrea M H Towlerton 1, Shashidhar Ravishankar 1, David G Coffey 1,2,3, Camille E Puronen 1,2, Edus H Warren 1,2; 1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 2 Division of Medical Oncology, University of Washington, Seattle, WA, United States. 3 Division of Hematology, University of Miami, Miami, FL, United States.

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Narayan V, et al.
Nature Medicine
May 2022
Authors and Affiliates
Vivek Narayan 1,2, Julie S Barber-Rotenberg 3, In-Young Jung #,2,3,4, Simon F Lacey #,3,5, Andrew J Rech #,2,3,5,6, Megan M Davis #,3, Wei-Ting Hwang 7, Priti Lal 2,5, Erica L Carpenter 2,6, Shannon L Maude 8,9, Gabriela Plesa 3, Neha Vapiwala 1,2, Anne Chew 3, Michael Moniak 3, Ronnie A Sebro 2,10, Michael D Farwell 2,10, Amy Marshall 3, Joan Gilmore 3, Lester Lledo 3, Karen Dengel 3, Sarah E Church 11, Tyler D Hether 11, Jun Xu 3, Mercy Gohil 3, Thomas H Buckingham 2,6, Stephanie S Yee 2,6, Vanessa E Gonzalez 3, Irina Kulikovskaya 3, Fang Chen 3, Lifeng Tian 3, Kyle Tien 2,6, Whitney Gladney 3, Christopher L Nobles 4, Hayley E Raymond 4, Prostate Cancer Cellular Therapy Program Investigators; Elizabeth O Hexner 1,2,3, Donald L Siegel 3,5, Frederic D Bushman 4, Carl H June #,12,13,14,15, Joseph A Fraietta #,16,17,18,19,20, Naomi B Haas #,21,22; 1 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 2 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 3 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 6 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA. 7 Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 8 Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 9 Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 10 Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 11 NanoString Technologies, Inc., Seattle, WA, USA. 12 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 13 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 14 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 15 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA. cjune@upenn.edu. 16 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 17 Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 18 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 19 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 20 Parker Institute for Cancer Immunotherapy, University of Pennsylvania, Philadelphia, PA, USA. jfrai@upenn.edu. 21 Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. naomi.haas@pennmedicine.upenn.edu. 22 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. naomi.haas@pennmedicine.upenn.edu. # Contributed equally.

Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients

Capelle CM, et al.
Cell Reports Medicine
May 2022
Authors and Affiliates
Christophe M Capelle 1,2, Séverine Ciré 1, Olivia Domingues 1, Isabelle Ernens 3, Fanny Hedin 4, Aurélie Fischer 3, Chantal J Snoeck 1, Wim Ammerlaan 5, Maria Konstantinou 4, Kamil Grzyb 6, Alexander Skupin 6,7, Cara L Carty 8, Christiane Hilger 1, Georges Gilson 9, Aljosa Celebic 10, Paul Wilmes 2,6, Antonio Del Sol 6,11,12, Ian M Kaplan 8, Fay Betsou 5,13, Tamir Abdelrahman 13, Antonio Cosma 4, Michel Vaillant 10, Guy Fagherazzi 3, Markus Ollert 1,14, Feng Q Hefeng 1; 1 Department of Infection and Immunity, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg. 2 Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. 3 Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg. 4 National Cytometry Platform, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg. 5 Integrated BioBank of Luxembourg (IBBL), Dudelange, Luxembourg. 6 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Belvaux, Luxembourg. 7 Department of Neuroscience, University California San Diego, La Jolla, CA, USA. 8 Adaptive Biotechnologies, Seattle, WA, USA. 9 Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg. 10 Translational Medicine Operations Hub, Competence Centre for Methodology and Statistics, Luxembourg Institute of Health, Strassen, Luxembourg. 11 CIC bioGUNE, Bizkaia Technology Park, Derio, Spain. 12 IKERBASQUE, Basque Foundation for Science, Bilbao, Spain. 13 Laboratoire National de Santé (LNS), Dudelange, Luxembourg. 14 Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), University of Southern Denmark, Odense, Denmark.

A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Wagner MJ, et al.
Clinical Cancer Research
May 2022
Authors and Affiliates
Michael J Wagner 1, Yuzheng Zhang 2, Lee D Cranmer 1, Elizabeth T Loggers, Graeme Black 3, Sabrina McDonnell 4, Shannon Maxwell 5, Rylee Johnson 5, Roxanne Moore 1, Pedro Hermida de Viveiros 6, Lauri Aicher 4, Kimberly S Smythe 4, Qianchuan He 3, Robin L Jones 7, Seth M Pollack 6; 1 University of Washington, Seattle, WA, United States. 2 Fred Hutchinson Cancer Research Center, Seattle, United States. 3 Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States. 5 Seattle Cancer Care Alliance, Seattle, United States. 6 Northwestern University, Chicago, IL, United States. 7Royal Marsden Hospital / Institute of Cancer Research, London, Chelsea, United Kingdom.

The T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy

Li D, et al.
Inflamm Bowel Dis
May 2022
Authors and Affiliates
Dalin Li 1, Alexander Xu 2, Emebet Mengesha 1, Rebecca Elyanow 3, Rachel M Gittelman 3, Heidi Chapman 3, John C Prostko 4, Edwin C Frias 4, James L Stewart 4, Valeriya Pozdnyakova 1, Philip Debbas 1, Angela Mujukian 1, Arash A Horizon 5, Noah Merin 2, Sandy Joung 6, Gregory J Botwin 1, Kimia Sobhani 7, Jane C Figueiredo 2, Susan Cheng 6, Ian M Kaplan 2, Dermot P B McGovern 1, Akil Merchant 2, Gil Y Melmed 1, Jonathan Braun 1,7; 1 *F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 2 Cedars Sinai Cancer and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3 Adaptive Biotechnologies, Seattle, WA, USA. 4 Applied Research and Technology, Abbott Diagnostics, Abbott Park, IL. 5 Center for Rheumatology Medical Group, Los Angeles, CA, USA. 6 Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 7 Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Bruton’s Tyrosine Kinase Supports Gut Mucosal Immunity and Commensal Microbiome Recognition in Autoimmune Arthritis

Bonami RH, et al.
Frontiers in Immunology
May 2022
Authors and Affiliates
Rachel H Bonami 1,2,3, Christina E Thurman 4, Sonam Verma 5, Camille S Westlake 4, Lindsay E Nyhoff 4, Bridgette B Barron 4, Andrea Reboldi 6, Peggy L Kendall 2,3,4,5; 1 Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States. 2 Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States. 3 Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4), Nashville, TN, United States. 4 Department of Medicine, Division of Allergy, Pulmonary, and Critical Care, Vanderbilt University Medical Center, Nashville, TN, United States. 5 Department of Medicine, Division of Allergy and Immunology, Washington University School of Medicine, St. Louis, MO, United States. 6 Department of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, United States.

Neoantigen-specific CD4 + T cells in human melanoma have diverse differentiation states and correlate with CD8 + T cell, macrophage, and B cell function

Veatch JR, et al.
Cancer Cell
May 2022
Authors and Affiliates
Joshua R Veatch 1, Sylvia M Lee 2, Carolyn Shasha 3, Naina Singhi 3, Julia L Szeto 3, Ata S Moshiri 4, Teresa S Kim 5, Kimberly Smythe 3, Paul Kong 3, Matthew Fitzgibbon 3, Brenda Jesernig 3, Shailender Bhatia 2, Scott S Tykodi 2, Evan T Hall 2, David R Byrd 5, John A Thompson 2, Venu G Pillarisetty 5, Thomas Duhen 6, A McGarry Houghton 3, Evan Newell 3, Raphael Gottardo 3, Stanley R Riddell 3; 1 Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: jveatch@fredhutch.org. 2 Department of Medical Oncology, University of Washington, Seattle, WA, USA. 3 Department of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4 Department of Dermatology, University of Washington, Seattle, WA, USA. 5 Department of Surgery, University of Washington, Seattle, WA, USA. 6 Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.
Previous Next